QIAGEN and ActiveSight Sign Co-Marketing Agreement Targeting Protein Crystallography

27-Feb-2006

Qiagen N.V. and ActiveSight, a protein crystallography service provider, announced that they have entered into a co-marketing agreement related to protein crystallography for drug discovery. The agreement seeks to ease access to protein crystallization reagents and crystallographic services, thereby expanding the opportunities for organizations in need of important structural biology information. Financial terms of the agreement were not disclosed.

According to QIAGEN the companie's line of standardized reagents and kits now enable researchers to use a seamless solution of QIAGEN products from genes all the way through to protein crystals. Crystal analysis and structure resolution can then be performed at ActiveSight, using their equipment for structural determination. ActiveSight also offers protein crystallization set-up using QIAGEN reagents.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances